Avacta targets Covid-19 test kit launch by end of Q1; cancer drug trial to get underway by mid-2021


Avacta said it was targeting a launch of its Covid-19 test kit by around the end of the first quarter of this year, as the diagonostics company touted progress on achieving full clinical validation to support a CE Mark.

In its therapeutics businesses, the said it had received authorisation from the UK's health regulatory, MHRA, to proceed with the phase 1 study of its lead pre|CISION platform drug candidate, AVA6000 Pro-doxorubicin.

The trial was was expected to begin in the middle of 2021.

'The significant progress achieved in both the Diagnostics and Therapeutics Divisions during 2020 has already enabled us to deliver major value inflection points during the first weeks of 2021,' the company said.

Preliminary results for the financial year ended 31 December 2020 were expected to be released mid-April.

Related content

Avacta signs distribution agreement with ABCAM for Covid-19 Affimer reagents

Cancer therapies and diagnostics group Avacta entered into a global distribution agreement with ABCAM to sell the company'sSARS-CoV-2 research Affimer reagents.

Under the worldwide, non-exclusive...

Tue, 06/04/2021 - 09:26

Avacta signs diagnostic licensing deal with Biokit

Cancer therapies and diagnostics group Avacta said it had entered into a license agreement with Biokit, a Werfen company, to incorporate its affimer reagents into...

Tue, 09/03/2021 - 09:55

Avacta wins approval from UK health authorities for cancer drug trial

Affimer biotherapeutics and reagents group Avacta said it had received approval from UK health authorities to move ahead with with its trial of its lead...

Thu, 18/02/2021 - 09:55

Avacta says Covid-19 test shows 'excellent' performance in clinical studies

Affimer biotherapeutics and reagents developer Avacta said it had received the first data showing 'excellent performance' of its SARS-CoV-2 rapid antigen test from ongoing clinical...

Tue, 16/02/2021 - 09:22

Avacta teamsp up with Mologic to market Covid-19 tests

Biotherapeutics company Avacta said it had entered into a commercial partnership with Mologic to market the company's SARS-CoV-2 lateral flow rapid antigen test.


Mon, 08/02/2021 - 09:50